POPULARITY
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don't miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.